60 Degrees Pharmaceuticals Inc
SXTP
Company Profile
Business description
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Contact
1025 Connecticut Avenue NW
Suite 1000
Washington, D.CWA20036
USAT: +1 202 327-5422
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
2
Stocks News & Analysis
stocks
The ASX healthcare player soaring to all-time highs
The steep market reaction comes after a recent announcement by the ACCC
stocks
Ask the analyst: How long is WiseTech's growth runway?
Roy Van Keulen answers my question on how big a growth opportunity remains for the ASX's biggest technology company.
video
Why the ASX's most overlooked world champion is no dinosaur
Brambles is the undisputed king of pallet pooling. Esther Holloway joined me to talk about its moat, growth prospects and risk of disruption.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,416.60 | 57.70 | -0.68% |
| CAC 40 | 7,541.36 | 63.58 | 0.85% |
| DAX 40 | 19,120.93 | 105.52 | 0.55% |
| Dow JONES (US) | 42,352.75 | 341.16 | 0.81% |
| FTSE 100 | 8,280.63 | 1.89 | -0.02% |
| HKSE | 22,736.87 | 623.36 | 2.82% |
| NASDAQ | 18,137.85 | 219.37 | 1.22% |
| Nikkei 225 | 38,635.62 | 83.56 | 0.22% |
| NZX 50 Index | 12,619.94 | 47.28 | 0.38% |
| S&P 500 | 5,751.07 | 51.13 | 0.90% |
| S&P/ASX 200 | 8,150.00 | 55.20 | -0.67% |
| SSE Composite Index | 3,336.50 | 248.97 | 8.06% |